Genomcore Raises €1 Million from Europe for Cancer Treatment

Public endorsement of Genomcore. The Spanish company has raised nearly €1 million from the European Next Generation funds for the development of a project to implement personalized medicine solutions for metastatic cancer patients.

The company aims to change clinical practice in the area of oncology with a commitment to personalized medicine. Specifically, based on a better understanding of each patient’s oncological disease, personalized treatment therapies will be made possible by targeting the molecular alterations identified.

For the identification of opportunities in European funds, Genomcore has had the support of Acció, the agency for the competitiveness of the company of the Departament d’Empresa de le Generalitat Catalana.

Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, and innovation in biotechnology.

Genomcore also operates the personalized health services brand Made of Genes

Genomcore is a specialist in digital solutions and data governance for the implementation of personalized medicine. Within the Dipcan project, the company is leading the integration of clinical, genomic, anatomy pathology, and radiological imaging data, which will enable the generation of several reports: a standardized clinical report, a digital histopathology report with corresponding images, a total body MRI report and a gene sequencing and expression report.

“This project allows us to develop the capabilities of our platform in a more multimodal approach,” Oscar Flores, CEO of Genomcore said. In this sense, he adds, “for the first time we will be able to test artificial intelligence algorithms with genetic data, medical images, and real-world data referring to patients.”

Founded in 2015 by computer engineer and biomedicine PhD Oscar Flores and clinician and digital health consultant Miquel Àngel Bru, Genomcore operates in the management and analysis of bio sanitary data for the implementation of personalized medicine, with a significant presence in Spain and Latin America. Genomcore also operates the personalized health services brand Made of Genes.

The company, headquartered in Esplugues de Llobregat (Barcelona), currently employs more than 35 professionals consisting of engineers, biomedical experts, and market specialists.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.